title: Nitazoxanide: a first-in-class broad-spectrum antiviral agent.
abstract: Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. A Phase 2b/3 clinical trial recently published in The Lancet Infectious Diseases found that oral administration of nitazoxanide 600mg twice daily for five days reduced the duration of clinical symptoms and reduced viral shedding compared to placebo in persons with laboratory-confirmed influenza. The same study also suggested a potential benefit for subjects with influenza-like illness who did not have influenza or other documented respiratory viral infection. From a chemical perspective, nitazoxanide is the scaffold for a new class of drugs called thiazolides. These small-molecule drugs target host-regulated processes involved in viral replication. Nitazoxanide is orally bioavailable and safe with extensive post-marketing experience involving more than 75 million adults and children. A new dosage formulation of nitazoxanide is presently undergoing global Phase 3 clinical development for the treatment of influenza. Nitazoxanide inhibits a broad range of influenza A and B viruses including influenza A(pH1N1) and the avian A(H7N9) as well as viruses that are resistant to neuraminidase inhibitors. It is synergistic with neuraminidase inhibitors, and combination therapy with oseltamivir is being studied in humans as part of ongoing Phase 3 clinical development. Nitazoxanide also inhibits the replication of a broad range of other RNA and DNA viruses including respiratory syncytial virus, parainfluenza, coronavirus, rotavirus, norovirus, hepatitis B, hepatitis C, dengue, yellow fever, Japanese encephalitis virus and human immunodeficiency virus in cell culture assays. Clinical trials have indicated a potential role for thiazolides in treating rotavirus and norovirus gastroenteritis and chronic hepatitis B and chronic hepatitis C. Ongoing and future clinical development is focused on viral respiratory infections, viral gastroenteritis and emerging infections such as dengue fever.
authors.affiliation: The Romark Institute for Medical Research, Tampa, FL, USA. Electronic address: jrossignol@romark.com.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Rossignol
mesh_terms: D000977:Antiparasitic Agents; D000998:Antiviral Agents / Q000494:pharmacology*; D004266:DNA Virus Infections / Q000188:drug therapy; D058492:Drug Repositioning; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D009574:Nitro Compounds; D013844:Thiazoles / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000977:Antiparasitic Agents; D000998:Antiviral Agents; D009574:Nitro Compounds; D013844:Thiazoles; C041747:nitazoxanide
keywords: Antiviral therapy; Broad-spectrum; Influenza; Nitazoxanide; Thiazolides
references.citation: Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8
references.pmid: 10952564
references.citation: Vet Med Int. 2010 Aug 12;2010:
references.pmid: 20847948
references.citation: Lancet. 2002 Nov 2;360(9343):1375-80
references.pmid: 12423984
references.citation: Am J Trop Med Hyg. 1984 May;33(3):511-2
references.pmid: 6731683
references.citation: J Antimicrob Chemother. 2006 Feb;57(2):353-5
references.pmid: 16361328
references.citation: Antimicrob Agents Chemother. 2009 Jan;53(1):281-6
references.pmid: 18955526
references.citation: Antimicrob Agents Chemother. 2010 Mar;54(3):1315-8
references.pmid: 20047919
references.citation: Antimicrob Agents Chemother. 1998 Nov;42(11):2836-40
references.pmid: 9797212
references.citation: J Infect Dis. 2001 Jul 1;184(1):103-6
references.pmid: 11398117
references.citation: Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9
references.pmid: 17517836
references.citation: Antimicrob Agents Chemother. 2014;58(4):2045-51
references.pmid: 24449767
references.citation: Antiviral Res. 2014 May;105:80-91
references.pmid: 24583027
references.citation: Curr Opin Virol. 2013 Apr;3(2):217-24
references.pmid: 23562753
references.citation: Aliment Pharmacol Ther. 2008 Sep 1;28(5):574-80
references.pmid: 18616643
references.citation: Lancet. 2006 Jul 8;368(9530):124-9
references.pmid: 16829296
references.citation: Expert Rev Anti Infect Ther. 2012 Oct;10(10):1129-38
references.pmid: 23199399
references.citation: J Clin Pharmacol. 2014 Sep;54(9):987-94
references.pmid: 24691901
references.citation: Virology. 2014 Aug;462-463:135-48
references.pmid: 24971706
references.citation: Virol J. 2014 Jan 23;11:10
references.pmid: 24456815
references.citation: Gastroenterology. 2009 Nov;137(5):1827-35
references.pmid: 19664635
references.citation: Antimicrob Agents Chemother. 2007 Mar;51(3):868-76
references.pmid: 17158936
references.citation: J Virol. 2013 Oct;87(20):11096-106
references.pmid: 23926336
references.citation: Antimicrob Agents Chemother. 2008 Nov;52(11):4069-71
references.pmid: 18710916
references.citation: J Med Chem. 2011 Dec 22;54(24):8670-80
references.pmid: 22059983
references.citation: Antiviral Res. 2011 Sep;91(3):233-40
references.pmid: 21703309
references.citation: ACS Med Chem Lett. 2011;2(11):849-854
references.pmid: 22096616
references.citation: Folia Parasitol (Praha). 2003 Mar;50(1):19-22
references.pmid: 12735719
references.citation: Antimicrob Agents Chemother. 1998 Nov;42(11):2877-82
references.pmid: 9797219
references.citation: Lancet Infect Dis. 2014 Jul;14(7):609-18
references.pmid: 24852376
references.citation: Aliment Pharmacol Ther. 2001 Sep;15(9):1409-15
references.pmid: 11552913
references.citation: Int J Infect Dis. 2009 Jul;13(4):518-23
references.pmid: 19070525
references.citation: Trans R Soc Trop Med Hyg. 2012 Mar;106(3):167-73
references.pmid: 22301075
references.citation: J Biol Chem. 2009 Oct 23;284(43):29798-808
references.pmid: 19638339
references.citation: J Infect. 2011 Nov;63(5):394-7
references.pmid: 21839773
references.citation: Antimicrob Agents Chemother. 1996 Oct;40(10):2266-70
references.pmid: 8891127
references.citation: Antimicrob Agents Chemother. 1998 Aug;42(8):1959-65
references.pmid: 9687390
references.citation: J Clin Gastroenterol. 2010 Aug;44(7):504-9
references.pmid: 20048684
references.citation: J Antimicrob Chemother. 2011 Jun;66(6):1407-8
references.pmid: 21393199
references.citation: J Med Chem. 2009 Oct 8;52(19):5789-92
references.pmid: 19736929
references.citation: Gastroenterology. 2009 Mar;136(3):856-62
references.pmid: 19135998
references.citation: Antiviral Res. 2008 Jan;77(1):56-63
references.pmid: 17888524
references.citation: Future Microbiol. 2008 Oct;3(5):539-45
references.pmid: 18811238
references.citation: Int J Clin Pharmacol Ther. 2000 Aug;38(8):387-94
references.pmid: 10984012
references.citation: J Med Chem. 2011 Jun 23;54(12):4119-32
references.pmid: 21553812
references.citation: Nat Biotechnol. 2012 Nov;30(11):1125-30
references.pmid: 23064238
references.citation: Clin Infect Dis. 2009 Feb 15;48(4):e41-6
references.pmid: 19133801
references.citation: Rev Med Virol. 2011 Nov;21(6):358-69
references.pmid: 21823192
references.citation: Clin Infect Dis. 2006 Aug 15;43(4):421-7
references.pmid: 16838229
references.citation: Aliment Pharmacol Ther. 2006 Nov 15;24(10):1423-30
references.pmid: 17081163
references.citation: Antimicrob Agents Chemother. 2006 Mar;50(3):1112-7
references.pmid: 16495282
references.citation: Antimicrob Agents Chemother. 2013 Jun;57(6):2821-3
references.pmid: 23478972
references.citation: Nat Rev Immunol. 2013 Jan;13(1):46-57
references.pmid: 23237964